- Home
- GMM vs NRXP Comparison
GMM vs NRXP Comparison
Compare GMM & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GMM | NRXP |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.6M | 63.5M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | GMM | NRXP |
|---|---|---|
| Price | $1.30 | $2.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.50 |
| AVG Volume (30 Days) | 14.3K | ★ 461.4K |
| Earning Date | 08-18-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.79 | N/A |
| Revenue | ★ $48,171,048.00 | $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $643.59 |
| P/E Ratio | $0.73 | ★ N/A |
| Revenue Growth | ★ 41.74 | N/A |
| 52 Week Low | $1.23 | $1.15 |
| 52 Week High | $4.97 | $6.01 |
Technical Indicators
Market Signals| Indicator | GMM | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 28.07 | 41.42 |
| Support Level | $1.25 | $2.22 |
| Resistance Level | $1.42 | $2.39 |
| Average True Range (ATR) | 0.09 | 0.16 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 18.21 | 40.74 |
Price Performance
Historical ComparisonAbout GMM Global Mofy Metaverse Limited
Global Mofy AI Ltd operates as a technology solutions provider engaged in virtual content production, digital marketing, and digital assets development for the metaverse industry. It utilizes its proprietary Mofy Lab technology platform which consists of three-dimensional (3D) rebuilt technology and artificial intelligence (AI) interactive technology to create a 3D high-definition virtual version of a wide range of physical world objects such as human, animal, and scenes which can be used in different applications.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.